Linagliptin

Sunan Sinadari:

8-[(3R) -3-aminoperidin-1-yl] -7- (amma-2-yn-1-yl) -3- methyl-1-[(4-methylquinazolin-2-yl) methyl]-3 ,7-dihydro-1H-purine-2,6-dione

Lambar SMILES:

O=C(N1CC2=NC(C)=C3C=CC=CC3=N2)N(C)C4=C(N(CC#CC)C(N5C[C@H](N)CCC5)=N4)C1 =O

Lambar InChi:

InChi=1S/C25H28N8O2/c1-4-5-13-32-21-22(29-24(32)31-12-8-9-17(26)14-31)30(3)25(35) 33(23(21 )34)15-20-27-16(2)18-10-6-7-11-19(18)28-20/h6-7,10-11,17H,8-9,12-15,26H2 ,1-3H3/t17-/m1/s1

InChi Key:

LTXREWYXXSTFRX-QGZVFWFLSA-N

Mabuɗin kalma:

Linagliptin, BI-1356, BI 1356, BI1356, 668270-12-0

Solubility:Mai narkewa a cikin DMSO

Ajiya:0 - 4°C na gajeren lokaci (kwanaki zuwa makonni), ko -20°C na dogon lokaci (watanni).

Bayani:

Linagliptin, wanda kuma aka sani da BI-1356, mai hana DPP-4 ne wanda Boehringer Ingelheim ya haɓaka don kula da nau'in ciwon sukari na II. Linagliptin (sau ɗaya a rana) FDA ta Amurka ta amince da ita a ranar 2 ga Mayu 2011 don maganin ciwon sukari na II. Boehringer Ingelheim da Lilly ne ke tallata shi.

Saukewa: DPP-4